Self-medication or excessive intake should always be avoided to minimise risks
The patient, a 22-year-old male with type A insulin resistance syndrome, experienced a reduction in HbA1c from 9.9% to 6.7% and substantial weight loss over two years
One of the latest trials (SUSTAIN FORTE) led to the approval of a higher semaglutide dose (2mg/weekly) for T2D, also reported a reduction in glycated hemoglobin of up to 2.2% from baseline [28]
To protect the medicine from light, you should replace the pen cap after each dose
In late 2023, the FDA added more than a dozen peptides including both BPC-157 and thymosin alpha 1 to its list of substances that should not be compounded because the agency has identified potential significant safety risks. For BPC-157, the agency warned that the peptide could trigger an immune response
Additionally, significant weight loss from GLP-1 therapy may eventually require levothyroxine dose adjustment, as thyroid hormone requirements can change with body composition changes